Body composition of lean women with polycystic ovary syndrome

Open access

Abstract

Polycystic ovary syndrome (PCOS) is one of the most frequent endocrine and metabolic disorders in reproductive age women, and it is related to changes in body size, shape and composition. Anthropometric somatotype is a quantitative description of the individual’s body shape and composition classified as endomorphy, mesomorphy or ectomorphy. Since PCOS somatotype has never previously been studied, here we evaluate body shape and composition phenomena in lean women with polycystic ovary syndrome and assess relationships with metabolic parameters. The study of 20-35 year-old women was carried out at the Department of Anatomy, Histology and Anthropology at Vilnius University. Standard anthropometric instruments and methods were used, and J. Matiegka’s equations calculated skeletal mass, skin and subcutaneous adipose tissue and muscles and internal organs. In addition, Heath - Carter’s somatotypes were computed, and the participants’ glucose, insulin, testosterone, sex hormone-binding globulin and lipid levels were established. We analysed data from 120 women with a mean age of 27.30 ± 3.68 years. Lean women with PCOS had greater skeletal mass by 0.47 kg (p<0.05, Cohen’s d=1.14), greater skin and subcutaneous adipose tissue mass by 2.79 kg (p<0.05, Cohen’s d=6.07) and lower muscle mass by 1.47 kg (p<0.05, Cohen’s d=2.84) compared to control women (p<0.05). The mean PCOS somatotype ratio was 4.96-4.38-3.00 (SD 1.50-1.26-1.11). This classified women with PCOS as mesomorphic endomorphs, in contrast to healthy women who were endomorphic mesomorphs. The PCOS subjects’ skin and subcutaneous adipose tissue and endomorphy/mesomorphy somatotype positively correlated with insulin levels and the HOMA-IR. It was established that lean women with polycystic ovary syndrome had a mesomorphic endomorph somatotype and higher skin and subcutaneous adipose tissue mass, but less muscle mass than healthy lean women. In addition, skin and subcutaneous adipose tissue positively correlated with insulin level and HOMA-IR in lean PCOS women.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • Allahbadia GN. Merchant R. 2011. Polycystic ovary syndrome and impact on health. Middle East Fertility Jourmal 16:19-37.

  • American Diabetes Association (ADA). Standards of medical care in diabetes -2009. Diabetes Care 2011; 34(Suppl 1): S11-61. Anthropometrica: a textbook of body measurement for sports and health courses. 2002. Norton K Olds T editors. Sidney: UNSW Press books.

  • Aydin K Cinar N Aksoy DY Bozdag G Yildiz BO. 2013. Body composition in lean women with polycystic ovary syndrome: effect of ethinyl estradiol and drospirenone combination. Contraception 87(3):358-62.

  • Azziz R Carmina E Dewailly D Diamanti- Kandarakis E Escobar-Morreale HF Futterweit W et al. 2009. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 91(2):456-88.

  • Baltadjiev AG. 2012. Somatotype characteristics of male patients with type 2 diabetes mellitus. Folia Med (Plovdiv) 54(2):40-5.

  • Barber TM Franks S. 2013. Adipocyte biology in polycystic ovary syndrome. Mol Cell Endocrinol 373(1-2):68-76.

  • Barber TM Golding SJ Alvey C Wass JA Karpe F Franks S et al. 2008. Global adiposity rather than abnormal regional fat distribution characterizes women with polycystic ovary syndrome. J Clin Endocrinol Metab 93(3):999-1004.

  • Bartoli E Fra GP Carnevale Schianca GP. 2011. The oral glucose tolerance test (OGTT) revisited. Eur J Intern Med 22(1):8-12.

  • Buffa R Floris G Putzu PF Carboni L Marini E. 2007a. Somatotype in elderly type 2 diabetes patients. Coll Antropol 31(3):733-7.

  • Buffa R Lodde M Floris G Zaru C Putzu PF Marini E. 2007b. Somatotype in Alzheimer’s disease. Gerontology 53(4):200-4.

  • Carmina E Bucchieri S Esposito A Del Puente A Mansueto P Orio F et al. 2007.Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. J Clin Endocrinol Metab 92(7):2500-5.

  • Carmina E Guastella E Longo RA Rini GB Lobo RA. 2009. Correlates of increased lean muscle mass in women with polycystic ovary syndrome. Eur J Endocrinol 161(4):583-9.

  • Carter JEL. 2002. The Heath-Carter antropometric somatotype. [pdf] Available at: http://www.somatotype.org/Heath-CarterManual.pdf [Accessed 9 Sep 2013].

  • Cosar E Ucok K Akgun L Koken G Sahin FK Arioz DT et al. 2008. Body fat composition and distribution in women with polycystic ovary syndrome. Gynecol Endocrinol 24(8):428-32.

  • Crosignani PG Colombo M Vegetti W Somigliana E Gessati A Ragni G. 2003.

  • Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices ovarian physiology and fertility rate induced by diet. Hum Reprod 18(9):1928-32.

  • Dantas WS Gualano B Rocha MP Barcellos CR dos Reis Vieira Yance V Marcondes JA. 2013. Metabolic disturbance in PCOS: clinical and molecular effects on skeletal muscle tissue. ScientificWorld Journal (in press).

  • Faulds G Ryden M Ek I Wahrenberg H Arner P. 2003. Mechanisms behind lipolytic catecholamine resistance of subcutaneous fat cells in the polycystic ovarian syndrome. J Clin Endocrinol Metab 88(5):2269-73.

  • Gennarelli G Holte J Berglund L Berne C Massobrio M Lithell H. 2000. Prediction models for insulin resistance in the polycystic ovary syndrome. Hum Reprod 15(10):2098-102.

  • Good C Tulchinsky M Mauger D Demers LM Legro RS. 1999. Bone mineral density and body composition in lean women with polycystic ovary syndrome. Fertil Steril. 72(1):21-5.

  • Hashimoto DM Schmid J Martins FM Fonseca AM Andrade LH Kirchengast S. 003. The impact of the weight status on subjective symptomatology of the Polycystic Ovary Syndrome: a cross-cultural comparison between Brazilian and Austrian women. Anthropol Anz 61(3):297-310.

  • Jakimavičienė EM Tutkuvienė J. 2004. Antropometriniai ir kiti kūno sudėties nustatymo metodai. (Antropomethry and other methods for assessment of body composition.) Medicinos teorija ir praktika 2(38):138-43

  • Kalichman L Kobyliansky E. 2006. Sex- and age-related variations of the somatotype in a Chuvasha population. Homo 57(2):151-62.

  • Kassanos D Trakakis E Baltas CS Papakonstantinou O Simeonidis G Salamalekis G et al. 2010. Augmentation of cortical bone mineral density in women with polycystic ovary syndrome: a peripheral quantitative computed tomography (pQCT) study. Hum Reprod 25:2107-14.

  • Katz A Nambi SS Mather K Baron AD Follmann DA Sullivan G et al. 2000. Quantitative insulin sensitivity check index: a simple accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 8:2402-10.

  • Kirchengast S Huber J. 2001. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod 16(6):1255-60.

  • Knussmann R Schwidetzky I Jurgens HW Ziegelmayer G. Antropologie. 1 Teil. 988. Stuttgart; Gustav Fischer Verlag.

  • Koleva M Nacheva A Boev M. 2002. Somatotype and disease prevalence in adults. Rev Environ Health 17(1):65-84.

  • Malina RM Katzmarzyk PT Song TMK Theriault G Bouchard C. 1997. Somatotype and cardiovascular risk factors in healthy adults. Am J Hum Biol 9:11-1.

  • Manneras-Holm L Leonhardt H Kullberg J Jennische E Oden A Holm G et al. 2011. dipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin but not circulating sex steroids are strongly associated with insulin resistance. J Clin Endocrinol Metab 96(2):E304-11.

  • March WA Moore VM Willson KJ Phillips DI Norman RJ Davies MJ. 2010. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 25(2):544-51.

  • Martin R Saller K. Lehrbuch Der Anthropologie. and II. 1959. Stuttgart: Gustav Fischer Verlag; p. 971-6.

  • Matthews DR Hosker JP Rudenski AS Naylor BA Treacher DF Turner RC. 1985. omeostasis model assessment: insulin resistance and β - cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-9.

  • McGarry JD. 2002. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 51(1):7-18.

  • Moran L Teede H. 2009. Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. Hum Reprod Update 15(4):477-88.

  • Padmanabhan V. 2009. Polycystic ovary syndrome - “A riddle wrapped in a mystery inside an enigma”. J Clin Endocrinol Metab 94(6):1883-5.

  • Penaforte FR Japur CC Diez-Garcia RW Chiarello PG. 2011. Upper trunk fat assessment and its relationship with metabolic and biochemical variables and body fat in polycystic ovary syndrome. J Hum Nutr Diet 24(1):39-46.

  • Puder JJ Varga S Kraenzlin M De Geyter C Keller U Muller B. 2005. Central Fat Excess in Polycystic Ovary Syndrome: Relation to Low-Grade Inflammation and Insulin Resistance. J Clin Endocrinol Metab 90(11):6014-21.

  • Saitoglu M Ardicoglu O Ozgocmen S Kamanli A Kaya A. 2007. Osteoporosis risk factors and association with somatotypes in males. Arch Med Res 38(7):746-51.

  • Schooling CM Jiang C Zhang W Lam TH Cheng KK Leung GM. 2011. Adolescent build and diabetes: the Guangzhou Biobank Cohort Study. Ann Epidemiol 21(1):61-6.

  • Snijder MB Dekker JM Visser M Bouter LM Stehouwer CD Yudkin JS et al. 2004. runk fat and leg fat have independent and opposite associations with fasting and postload glucose levels: the Hoorn study. Diabetes Care 27(2):372-7.

  • Sterkowicz-Przybycien K Almansba R. 2011. Sexual dimorphism of anthropometrical measurements in judoists vs. untrained subject. Sci Sports 26:316-23.

  • Sterkowicz-Przybycien K. 2009. Body composition and somatotype of the elite of Polish fencers. St Coll Antropol 33(3):765-72.

  • Svendsen PF Nilas L Norgaard K Jensen JE Madsbad S. 2008. Obesity body composition and metabolic disturbances in polycystic ovary syndrome. Hum Reprod 23(9):2113-21.

  • The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. 2004. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19:41-7.

  • To M Wong MA. 2005. Comparison of bone mineral density in oligomenorrhoeic adolescents with polycystic ovaries and normal ovaries. Gynecol Endocrinol 20:237-42.

  • Toscani M Migliavacca R Sisson de Castro JA Spritzer PM. 2007. Estimation of truncal adiposity using waist circumference or the sum of trunk skinfolds: a pilot study for insulin resistance screening in hirsute patients with or without polycystic ovary syndrome. Metabolism 56(7):992-7.

  • Tutkuvienė J Jakimavičienė EM. 2004. Kūno sudėjimo rodikliai ir jų sąsajos su bendra sveikatos būkle. (Indices of body frame and their connections with general health status.) Medicinos teorija ir praktika 1(37):59-63. Vermeulen A Verdonck L Kaufman JM. 1999. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84:3666-72.

  • Villa J Pratley RE. 2011. Adipose tissue dysfunction in polycystic ovary syndrome. Curr Diab Rep 11(3):179-84.

  • Williams SR Goodfellow J Davies B Bell W McDowell I Jones E. 2000. Somatotype and angiographically determined atherosclerotic coronary artery disease in men. Am J Hum Biol 12(1):128-38.

  • World Health Organization: Definition and Diagnosis of Diabetes Mellitus and intermediate hyperglycaemia: Report of a WHO/IDF Consultation. 2006. Geneva World Health Org.

  • Yildirim B Sabir N Kaleli B. 2003. Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome. Fertil Steril 79:1358-64.

  • Yucel A Noyan V Sagsoz N. 2006. The association of serum androgens and insulin resistance with fat distribution in polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 126(1):81-6.

  • Zabulienė L Kučinskienė ZA Jakimavičienė EM Drąsutienė G Tutkuvienė J. 2012. Policistinių kiaušidžių sindromu sergančių moterų hiperandrogenizmo matai ir jų kritinės reikšmės. (Indices and cutoff points for hyperandrogenism in woman with polycystic ovary syndrome.) Laboratorinė medicina 14-1(5348):8-17.

  • Zborowski J Cauley J Talbott E Guzick D Winters J. 2000. Bone mineral density androgens and the polycystic ovary: the complex and controversial issue of androgenic influence on female bone. J Clin Endocrinol Metab 85:3496-506.

Search
Journal information
Impact Factor


CiteScore 2018: 0.55

SCImago Journal Rank (SJR) 2018: 0.22
Source Normalized Impact per Paper (SNIP) 2018: 0.472

Cited By
Metrics
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 307 141 3
PDF Downloads 126 65 0